Technology area: Biotechnology & Pharmaceuticals
8 pending office actions • 4 art units • 6 examiners • 0 of 8 (0%) have an AI response strategy ready • 11 patents granted in the last 365 days
Halozyme Inc. has 8 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 6 examiners and 3 art units, showing a compact art-unit footprint with some examiner diversity.
HOLLAND, PAUL J is the busiest examiner, with 3 pending matters. Counsel can use the repeated assignment to identify examiner-specific practices while organizing the remaining files by their art-unit context.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (12%) |
| §112 only | 2 (25%) |
| Double-patenting only | 1 (12%) |
| Double-patenting + other | 2 (25%) |
| Multi-statute (no §101) | 2 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HOLLAND, PAUL J | 3 | 57.3% | +64.7% |
| BENAVIDES, JENNIFER ANN | 1 | 50.8% | +47.3% |
| MEAH, MOHAMMAD Y | 1 | 70.7% | +42.8% |
| STEADMAN, DAVID J | 1 | 57.7% | +29.7% |
| NOAKES, SUZANNE MARIE | 1 | 73.4% | +18.3% |
| SHAH, NILAY J | 1 | 76.3% | +46.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19358181 | METHODS OF TREATING TUMORS | BENAVIDES, JENNIFER ANN | 2d overdue |
| 19071092 | PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF | NOAKES, SUZANNE MARIE | — |
| 18927335 | PREFILLED SYRINGE INJECTOR | SHAH, NILAY J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19071264 | PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF | STEADMAN, DAVID J | 125d overdue |
| 19358181 | METHODS OF TREATING TUMORS | BENAVIDES, JENNIFER ANN | 2d overdue |
| 19550136 | PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF | HOLLAND, PAUL J | — |
| 19550132 | PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF | HOLLAND, PAUL J | — |
| 19307581 | Hyaluronidase Enzyme Formulations for High Volume Administration | MEAH, MOHAMMAD Y | — |
| 19071092 | PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF | NOAKES, SUZANNE MARIE | — |
| 18927335 | PREFILLED SYRINGE INJECTOR | SHAH, NILAY J | — |
| 18882496 | MODIFIED HYALURONIDASES AND USES IN TREATING HYALURONAN-ASSOCIATED DISEASES AND CONDITIONS | HOLLAND, PAUL J | — |
| Art Unit | Apps |
|---|---|
| 1656 | 4 |
| 1675 | 1 |
| 1652 | 1 |
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19550136 | PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF | HOLLAND, PAUL J | 1656 | §112DP | Non-Final OA | — | Pending | Feb 25, 2026 |
| 19550132 | PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF | HOLLAND, PAUL J | 1656 | §112 | Final Rejection | — | Pending | Feb 25, 2026 |
| 19358181 | METHODS OF TREATING TUMORS | BENAVIDES, JENNIFER ANN | 1675 | §103§112Other | Final Rejection | 2d overdue | Pending | Oct 14, 2025 |
| 19307581 | Hyaluronidase Enzyme Formulations for High Volume Administration | MEAH, MOHAMMAD Y | 1652 | DP | Non-Final OA | — | Pending | Aug 22, 2025 |
| 19071264 | PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF | STEADMAN, DAVID J | 1656 | §112DP | Non-Final OA | 125d overdue | Pending | Mar 05, 2025 |
| 19071092 | PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF | NOAKES, SUZANNE MARIE | 1656 | §101§112DP | Non-Final OA | — | Pending | Mar 05, 2025 |
| 18927335 | PREFILLED SYRINGE INJECTOR | SHAH, NILAY J | — | §102§103 | Non-Final OA | — | Pending | Oct 25, 2024 |
| 18882496 | MODIFIED HYALURONIDASES AND USES IN TREATING HYALURONAN-ASSOCIATED DISEASES AND CONDITIONS | HOLLAND, PAUL J | 1653 | §112Other | Non-Final OA | — | Pending | Sep 11, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHalozyme Inc. has 8 pending office actions as of October 2026, spread across 4 art units and 6 examiners.
Paul J Holland has the most, with 3 of Halozyme Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
